» Articles » PMID: 26809747

Immunoregulatory Forkhead Box Protein P3-Positive Lymphocytes Are Associated with Overall Survival in Patients with Pancreatic Neuroendocrine Tumors

Overview
Journal J Am Coll Surg
Date 2016 Jan 27
PMID 26809747
Citations 18
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Forkhead box protein p3-positive (FoxP3(+)) regulatory T cells (Tregs) suppress host T-cell-mediated immune responses, limit surveillance against cancers, and have been associated with a poor prognosis.

Study Design: This study aims to identify the prognostic significance of FoxP3(+) Tregs in pancreatic neuroendocrine tumors (PNETs). Patients diagnosed with PNETs between 1992 and 2014 (n = 101) were included in this retrospective analysis. Clinical data, histopathology, and expression of FoxP3(+) Tregs and Ki-67 by immunohistochemistry were assessed. The association of these factors with survival was tested by log-rank test and in additional multivariable analysis.

Results: A total of 101 patients were included in this study. Mean age was 58.0 years (range 18 to 87 years) and median tumor size was 25 mm (range 8 to 160 mm). The degree of infiltration of tumor by FoxP3(+) Tregs was graded as 0 (n = 75), 1 (n = 15), or 2 (n = 11). Median follow-up was 50 months (interquartile range 123 months; Q1 = 20 months and Q3 = 123 months). In univariate analyses, patient age older than 57 years, TNM stage III or IV, tumor size >25 mm, Ki-67 labeling index >20, and a high number of FoxP3(+) tumor-infiltrating lymphocytes were significantly associated with poorer overall survival. In multivariable analyses, FoxP3(+) expression score of 2 (hazard ratio = 6.9; 95% CI 1.4-34.4) was the only statistically significant predictor for overall mortality.

Conclusions: FoxP3(+) Treg expression is an independent prognostic factor in patients with PNETs, associated with statistically significant shorter overall survival. There is a role for additional research into the immune-mediated role of FoxP3(+) Tregs in PNETs.

Citing Articles

Association between rs3761548 polymorphism of and the risk of gastric cancer: a case-control study.

Validi S, Saadat I Mol Biol Res Commun. 2024; 13(4):247-252.

PMID: 39315286 PMC: 11416849. DOI: 10.22099/mbrc.2024.49125.1989.


Immunotherapy in Neuroendocrine Neoplasms: A Diamond to Cut.

Garcia-Torralba E, Garcia-Lorenzo E, Doger B, Spada F, Lamarca A Cancers (Basel). 2024; 16(14).

PMID: 39061170 PMC: 11275146. DOI: 10.3390/cancers16142530.


Circulating Regulatory T Cells: A Novel Marker Associated with Liver Metastasis and the Treatment Response of Transarterial Embolization in Gastroenteropancreatic Neuroendocrine Tumors.

Liu M, Yu H, Chen L, Yang D, Liu H, Ouyang J Neuroendocrinology. 2023; 114(9):827-839.

PMID: 38061350 PMC: 11410302. DOI: 10.1159/000535385.


Characterization of circulating immune cells and correlation with Tie2/Angiopoietins level in well differentiated neuroendocrine gastroenteropancreatic tumors: a cross-sectional analysis.

Sesti F, Puliani G, Feola T, Campolo F, Sciarra F, Hasenmajer V Endocrine. 2022; 80(1):221-230.

PMID: 36509928 DOI: 10.1007/s12020-022-03257-8.


The Landscape and Clinical Application of the Tumor Microenvironment in Gastroenteropancreatic Neuroendocrine Neoplasms.

Xu S, Ye C, Chen R, Li Q, Ruan J Cancers (Basel). 2022; 14(12).

PMID: 35740577 PMC: 9221445. DOI: 10.3390/cancers14122911.